New clinical evidence suggests that Novera Retatrutide, a dual-action treatment from Novo Nordisk, could provide a significant breakthrough in body management. Unlike many existing drugs, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and GIP, potentially resulting to greater reductions… Read More